E-Mail
Lifestyle, or put another way bad habits , is one of the textbook explanations for why some people are at higher risk for cancer. We often hear that smoking increases our risk of developing lung cancer or that a high-fat diet increases our risk of developing bowel cancer, but not all smokers get lung cancer and not all people who eat cheeseburgers get bowel cancer. Other factors must be at play.
Now, new research from University of Calgary scientist Dr. Edwin Wang, PhD, is shedding light on those other factors . Wang has discovered seven DNA fingerprints or patterns that define cancer risk. The research is published in
International trials of blood thinners in critically ill COVID-19 patients pause due to futility medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Researchers test effects of full doses of anticoagulants in COVID-19 patients
Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients.
Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, full-dose anticoagulation drugs did not improve outcomes. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.
As is normal for clinical trials, these trials are overseen by independent boards that routinely review the data and are composed of experts in ethics, biostatistics, clinical trials, and blood clotting disorders. Informed by the deliberations of these oversight boards, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19.
Date Time
Medicine by Design symposium highlights importance of convergence in regenerative medicine and human health
Researchers are poised to make unprecedented breakthroughs in human health thanks to advances in biomedical and computational sciences that have driven critical tools and technologies such as genetic engineering, synthetic biology, and artificial intelligence.
That’s the message Dr. Victor Dzau, president of the U.S. National Academy of Medicine, delivered to Medicine by Design’s fifth annual symposium on Dec. 7 and 8.
The virtual event, which attracted more than 500 registrants from across North America, focused on the theme of better science through convergence – the integration of approaches from engineering, science, medicine and other fields to expand knowledge and spark innovation.